Respiratory tract microbial pathogens

Respiratory tract microbial pathogens represent a broad category of infectious agents, including bacteria, viruses, and fungi, that target the human respiratory system [3, 11]. These pathogens are responsible for a wide spectrum of diseases, from mild upper respiratory tract infections like the common cold and sinusitis to severe lower respiratory tract conditions such as pneumonia and tuberculosis [4, 13]. Common bacterial examples include Streptococcus pneumoniae and Haemophilus influenzae, while viral pathogens include influenza viruses, respiratory syncytial virus (RSV), and coronaviruses like SARS-CoV-2 [3, 6, 11]. These organisms employ diverse mechanisms to colonize the respiratory mucosa, evade host immune responses, and cause tissue damage through toxins or inflammatory triggers [4, 12]. Therapeutic intervention against these pathogens involves the use of anti-infective drugs tailored to the specific type of microbe [7, 8]. Antibiotics such as beta-lactams and macrolides target bacterial cell wall synthesis and protein production, respectively, while antivirals like oseltamivir and remdesivir inhibit viral replication cycles [11, 13]. The clinical management of these infections is often guided by biomarkers like procalcitonin and C-reactive protein to distinguish between bacterial and viral etiologies [1, 5, 9]. However, the effectiveness of these treatments is increasingly challenged by the global rise of antimicrobial resistance and the emergence of novel viral strains [6, 10].

Other names

Respiratory pathogensLung pathogensRTI-causing organismsPulmonary pathogens

Drugs targeting these pathogens employ diverse mechanisms: beta-lactam antibiotics (e.g., amoxicillin) inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins [4, 13]; macrolides (e.g., azithromycin) and tetracyclines inhibit protein synthesis by binding to the 50S or 30S ribosomal subunits [6, 13]; fluoroquinolones (e.g., levofloxacin) inhibit DNA gyrase and topoisomerase IV [13]; neuraminidase inhibitors (e.g., oseltamivir) prevent the release of viral progeny [11]; and RNA polymerase inhibitors (e.g., remdesivir) block viral genome replication [11].